Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An update from Lepu Biopharma Co. Ltd. Class H ( (HK:2157) ) is now available.
Lepu Biopharma Co., Ltd. successfully held its 2024 Annual General Meeting (AGM) on June 27, 2025, where all proposed resolutions were approved by shareholders. The resolutions included approval of financial reports, profit distribution plans, and the re-appointment of Ernst & Young as auditors, reflecting strong shareholder support and strategic alignment for the company’s future operations.
More about Lepu Biopharma Co. Ltd. Class H
Lepu Biopharma Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating within the biopharmaceutical industry. The company is focused on developing and commercializing innovative medicines, with a market focus on addressing unmet medical needs.
Average Trading Volume: 24,415,556
Technical Sentiment Signal: Buy
Current Market Cap: HK$9.58B
Find detailed analytics on 2157 stock on TipRanks’ Stock Analysis page.